News for Ultragenyx Pharmaceutical Inc. (RARE)

Summary Ultragenyx Pharmaceutical Inc (RARE), a biopharmaceutical company dedicated to developing therapies for rare and ultrarare genetic diseases, announced o

NOVATO, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. ( RARE), a biopharmaceutical company focused on the development and commercia

**media[545030]**

Summary Ultragenyx Pharmaceutical Inc (RARE) has announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA)

FDA decision expected by August 18, 2025 NOVATO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. ( RARE) today announced the U.S. F

The following slide deck was published by Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ETCompany ParticipantsJoshua Higa - VP, IREmil...

**media[540325]**

On December 31, 2024, Frank Sands (Trades, Portfolio), CEO and CIO of Sands Capital Management, executed a significant reduction in holdings of Ultragenyx Pharm

Summary Ultragenyx Pharmaceutical Inc (RARE), a biopharmaceutical company dedicated to developing treatments for rare and ultrarare genetic diseases, has announ

NOVATO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. ( RARE), a biopharmaceutical company focused on the development and commercia

**media[534598]**

Ultragenyx Pharmaceutical is a mid-cap biotech firm with a promising pipeline and an optimistic outlook from analysts. Click here to read why RARE is a Hold.

Summary Ultragenyx Pharmaceutical Inc (RARE), a biopharmaceutical company dedicated to developing therapies for rare and ultrarare diseases, announced on Januar

**media[518150]**

Ultragenyx Pharmaceutical Inc (RARE), a biopharmaceutical company specializing in rare and ultrarare genetic diseases, announced preliminary unaudited revenue r

Mereo BioPharma Provides Update on Lead Clinical Programs

Preliminary 2024 total revenue of $555 million to $560 million, exceeding top end of guidance, including Crysvita® revenue of $405 million to $410 million, and

LONDON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc ( MREO) (”œMereo” or the ”œCompany”), a clinical-stage biopharmaceutical company foc